Jessica L. Huggins, Edward Lyman, Pamela Martínez-Loustalot, Christie J. McMillan, Adam A. Pack, Ester Quintana-Rizzo, Nicola Ransome, Tasli J. H. Shaw, Andy Szabo, Leigh Torres, Jorge Urbán R., Martin van Aswegen, Janie Wray, Jeffrey Moore. 2025. Harnessing the power of photo-ID data for apportionment to migratory whale herds: U.S. West Coast humpback whale stock proportions by latitude for the period 2019–2024. U.S. Department of Commerce, NOAA Technical Memorandum NMFS–SWFSC–723. *https://doi.org/10.25923/ah7d-sj35.*

Edwards, E.F., Hall, C., Moore, T.J., Sheredy, C. and Redfern, J.V., 2015. Global distribution of fin whales Balaenoptera physalus in the post-whaling era (1980–2012). Mammal Review, 45(4), pp.197–214.

Martien, K.K., Taylor, B.L., Archer, F.I., Audley, K., Calambokidis, J., Cheeseman, T. De Weerdt, J., Frisch Jordán, A., Martínez-Loustalot, P., Ortega-Ortiz, C.D., Patterson, E.M., Ransome, N., Ruvelas, P., Urbán Ramírez, J., and Villegas-Zurita, F. 2021. Evaluation of Mexico Distinct Population Segment of Humpback Whales as units under the Marine Mammal Protection Act. U.S. Department of Commerce, NOAA Technical Memorandum NMFS–SWFSC–658. *https://doi.org/10.25923/nvw1-mz45.*

Mizroch, S.A., D. Rice, D. Zwiefelhofer, J. Waite, and W. Perryman. 2009. Distribution and movements of fin whales in the North Pacific Ocean. Mammal Rev. 39(3):193–227.

Stafford, K.M., S.L. Nieukirk, and C.G. Fox. 1999. An acoustic link between blue whales in the eastern tropical Pacific and the Northeast Pacific. Mar. Mamm. Sci. 15(4):1258–1268.

Stafford, K.M., S.L. Nieukirk, and C. G. Fox. 2001. Geographic and seasonal variation of blue whale calls in the North Pacific. Journal Cetacean Research and Management. 3:65–76.

Taylor, B.L., Martien, K.K., Archer, F.I., Audley, K., Calambokidis, J., Cheeseman, T., De Weerdt J., Frisch Jordán, A., Martínez-Loustalot, P., Ortega-Ortiz, C.D., Patterson, E.M., Ransome, N., Ruvelas, P., and Urbán Ramírez, J. 2021. Evaluation of humpback whales wintering in Central America and southern Mexico as a demographically independent population. U.S. Department of Commerce, NOAA Technical Memorandum NMFS–SWFSC–655. *https://doi.org/10.25923/sgek-1937.*

Wade, P.R., E.M. Oleson, and N.C. Young. 2021. Evaluation of Hawai'i distinct population segment of humpback whales as units under the Marine Mammal Protection Act. U.S. Dep. Commer., NOAA Tech. Memo. NMFSAFSC–430, 31 p.

Dated: October 31, 2025.

Samuel D. Rauch, III,

Deputy Assistant Administrator for Regulatory Programs, National Marine Fisheries Service.

[FR Doc. 2025–19776 Filed 10–31–25; 4:15 pm]

BILLING CODE 3510–22–P

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No.: PTO–C–2025–0281]

Performance Review Board

AGENCY: United States Patent and Trademark Office, Commerce.

ACTION: Notice of revised board members and agency appointing authority.

SUMMARY: In conformance with the Civil Service Reform Act of 1978, the United States Patent and Trademark Office (USPTO) announces the appointment of persons to serve as members of its Performance Review Board (PRB). This is an update to the recently published **Federal Register** notice (published on July 25, 2025), to reflect board members serving in the role of their official position of record as the Deputy Under Secretary of Commerce for Intellectual Property and Deputy Director of the USPTO and the Chief Compliance Officer.

ADDRESSES: Office of Human Resources, USPTO, P.O. Box 1450, Alexandria, VA 22313–1450.

FOR FURTHER INFORMATION CONTACT: Carolyn Schad, Acting Director, Human Capital Management, USPTO, at 571–272–7003.

SUPPLEMENTARY INFORMATION: The membership of the USPTO's PRB is as follows:

Coke M. Stewart, Chair, Deputy Under Secretary of Commerce for Intellectual Property and Deputy Director of the USPTO

William Covey, Chief Compliance Officer, USPTO

Christopher J. Shipp, Chief of Staff, USPTO

Anne T. Mendez, Vice Chair, Acting Chief Administrative Officer, USPTO

Valencia Martin-Wallace, Acting Commissioner for Patents, USPTO

John A. Squires,

Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office.

[FR Doc. 2025–19774 Filed 11–3–25; 8:45 am]

BILLING CODE 3510–16–P

FARM CREDIT ADMINISTRATION

Sunshine Act Meetings

TIME AND DATE: 10 a.m., Thursday, November 13, 2025.

PLACE: You may observe the open portions of this meeting in person at 1501 Farm Credit Drive, McLean, Virginia 22102–5090, or virtually. If you would like to observe, at least 24 hours in advance, visit *FCA.gov,* select ''Newsroom,'' then select ''Events.'' From there, access the linked ''Instructions for board meeting visitors'' and complete the described registration process.

STATUS: Parts of this meeting will be open to the public. The rest of the meeting will be closed to the public.

MATTERS TO BE CONSIDERED: The following matters will be considered:

PORTIONS OPEN TO THE PUBLIC:

- Approval of October 9, 2025, Minutes
- Report on Veterans in Agriculture

PORTIONS CLOSED TO THE PUBLIC:

- Office of Secondary Market Oversight Periodic Report [1]

CONTACT PERSON FOR MORE INFORMATION: If you need more information or assistance for accessibility reasons, or have questions, contact Ashley Waldron, Secretary to the Board. Telephone: 703–883–4009. TTY: 703–883–4056.

Ashley Waldron,

Secretary to the Board.

[FR Doc. 2025–19767 Filed 10–31–25; 4:15 pm]

BILLING CODE 6705–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2025–N–4679]

Circulatory System Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—V-Wave Ventura Interatrial Shunt System

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; establishment of a public docket; request for comments.

SUMMARY: The Food and Drug Administration (FDA) is announcing a forthcoming public advisory committee meeting of the Circulatory System Devices Panel of the Medical Devices

[1] Session Closed-Exempt pursuant to 5 U.S.C. 552b(c)(8)and(9).

Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to the Agency on FDA's regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.

DATES: The meeting will take place virtually on December 3, 2025, from 9 a.m. to 6 p.m. Eastern Time.

ADDRESSES: All meeting participants will be heard, viewed, captioned, and recorded for this advisory committee meeting via an online teleconferencing and/or video conferencing platform. Answers to commonly asked questions about FDA advisory committee meetings may be accessed at: *https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm*.

FDA is establishing a docket for public comment on this meeting. The docket number is FDA–2025–N–4679. The docket will close on January 3, 2026. Please note that late, untimely filed comments will not be considered. The *https://www.regulations.gov* electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of January 3, 2026. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date.

Comments received on or before November 14, 2025 will be provided to the Committee. Comments received after that date will be taken into consideration by FDA. In the event that the meeting is cancelled, FDA will continue to evaluate any relevant applications or information, and consider any comments submitted to the docket, as appropriate.

You may submit comments as follows:

Electronic Submissions

Submit electronic comments in the following way:

- *Federal eRulemaking Portal: https://www.regulations.gov.* Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to *https://www.regulations.gov* will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on *https://www.regulations.gov*.
- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ''Written/Paper Submissions'' and ''Instructions'').

Written/Paper Submissions

Submit written/paper submissions as follows:

- *Mail/Hand Delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked, and identified, as confidential, if submitted as detailed in ''Instructions.''

Instructions: All submissions received must include the Docket No. FDA–2025–N–4679 for ''Circulatory System Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments.''

Received comments, those filed in a timely manner (see **ADDRESSES**), will be placed in the docket and, except for those submitted as ''Confidential Submissions,'' publicly viewable at *https://www.regulations.gov* or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500.

- Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ''THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' FDA will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on *https://www.regulations.gov*. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify the information as ''confidential.'' Any information marked as ''confidential'' will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: *https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf*.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to *https://www.regulations.gov* and insert the docket number, found in brackets in the heading of this document, into the ''Search'' box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240–402–7500.

FOR FURTHER INFORMATION CONTACT: Kendra Brooks, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm.1564, Silver Spring, MD 20993–0002, 240–402–2977, *Kendra.Brooks@fda.hhs.gov*. A notice in the **Federal Register** about last-minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check FDA's website at *https://www.fda.gov/AdvisoryCommittees/default.htm* and scroll down to the appropriate advisory committee meeting link to learn about possible modifications before the meeting.

SUPPLEMENTARY INFORMATION:

Agenda: The meeting will be virtual. The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing and/or video conferencing platform. On December 3, 2025, the Committee will discuss, make recommendations, and vote on information regarding the premarket approval application (PMA) sponsored by V-Wave, Inc. for the V-Wave Ventura Interatrial Shunt System, which is a first-of-a-kind device permanent implant designed to shunt blood from the left to the right atrium to improve symptoms in patients with advanced chronic heart failure. The proposed Indication for Use statement is as follows: The V-Wave Ventura Interatrial Shunt System is indicated for New York Heart Association (NYHA) Class III heart failure patients who remain symptomatic despite guideline directed medical therapy and have a left ventricular ejection fraction of ≤40%, and who are judged by a Heart Team to be appropriate for Shunt therapy, to

reduce the risk of hospitalization for heart failure. The device is proposed to be used in patients who have already been treated with all other device and drug treatment options appropriate for them.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available on FDA's website at the time of the advisory committee meeting, and the background material will be posted on FDA's website after the meeting. Background material and the link to the online teleconference and/or video conference meeting will be available at *https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm*. Scroll down to the appropriate advisory committee meeting link. The meeting will include slide presentations with audio and video components to allow the presentation of materials in a manner that most closely resembles an in-person advisory committee meeting.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the Committee. All electronic and written submissions submitted to the Docket (see **ADDRESSES**) on or before November 14, 2025, will be provided to the Committee. Oral presentations from the public will be scheduled on December 3, 2025, between approximately 2 p.m. and 3 p.m. Eastern Time. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before November 3, 2025. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by November 10, 2025.

For press inquiries, please contact the FDA Newsroom at *www.fda.gov/news-events/fda-newsroom*.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact CDR Daniel Bailey at *Daniel.Bailey@fda.hhs.gov* or 301–796–0048 at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our website at *https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm* for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. 1001 *et seq.*). This meeting notice also serves as notice that, pursuant to 21 CFR 10.19, the requirements in 21 CFR 14.22(b), (f), and (g) relating to the location of advisory committee meetings are hereby waived to allow for this meeting to take place using an online meeting platform. This waiver is in the interest of allowing greater transparency and opportunities for public participation, in addition to convenience for advisory committee members, speakers, and guest speakers. The conditions for issuance of a waiver under 21 CFR 10.19 are met.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2025–19762 Filed 11–3–25; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF THE INTERIOR

Bureau of Ocean Energy Management

[Docket No. BOEM–2025–0020]

Notice on Outer Continental Shelf Oil and Gas Lease Sales

AGENCY: Bureau of Ocean Energy Management, Interior.

ACTION: List of restricted joint bidders.

SUMMARY: Pursuant to the Energy Policy and Conservation Act of 1975 and the Bureau of Ocean Energy Management's (BOEM) regulatory restrictions on joint bidding, BOEM is publishing this list of restricted joint bidders. Each entity within one of the following groups is restricted from bidding with any entity in any of the other groups listed below at Outer Continental Shelf oil and gas lease sales held during the bidding period of November 1, 2025, through April 30, 2026.

DATES: This list of restricted joint bidders covers the bidding period of November 1, 2025, through April 30, 2026, and succeeds all prior published lists.

SUPPLEMENTARY INFORMATION:

Group I

BP America Production Company
BP Exploration & Production Inc.
BP Products North America, Inc.

Group II

Chevron Corporation
Chevron U.S.A. Inc.
Unocal Corporation
Union Oil Company of California
Noble Energy, Inc.
Hess Corporation
Chevron Midcontinent, L.P.

Group III

Eni Marketing Inc.
Eni BB Petroleum Inc.
Eni US Operating Co. Inc.
Eni Petroleum Co. Inc.
Eni Next LLC
Eni USA Gas Marketing LLC
Eni GoM LLC
Versalis Americas Inc.
Eni Trading & Shipping Inc.

Group IV

Equinor ASA
Equinor Gulf of Mexico LLC
Equinor USA E&P Inc.

Group V

Exxon Mobil Corporation
ExxonMobil Upstream Company

Group VI

Shell USA, Inc.
Shell Offshore Inc.
SWEPI LP
Shell Frontier Oil & Gas Inc.
SOI Finance Inc.
Shell Gulf of Mexico Inc.

Group VII

TotalEnergies E&P USA, Inc.
TotalEnergies SE

Even if an entity does not appear on the above list, BOEM may disqualify and reject certain joint or single bids submitted by an entity if that entity is chargeable for the prior production period with an average daily production in excess of 1.6 million barrels of crude oil, natural gas, and natural gas liquids. *See* 30 CFR 556.512.

Authority: 42 U.S.C. 6213; and 30 CFR 556.511–556.515.

Matthew N. Giacona,

Acting Director, Bureau of Ocean Energy Management.

[FR Doc. 2025–19780 Filed 11–3–25; 8:45 am]

BILLING CODE 4340–98–P

NATIONAL CREDIT UNION ADMINISTRATION

Sunshine Act Meetings

TIME AND DATE: 1:00 p.m., Wednesday, November 5, 2025.